Natco Pharma Reports Flat December 2024 Results Amid Profit Decline and Low Sales
Natco Pharma has recently experienced an evaluation adjustment reflecting its financial performance, reporting flat results for the quarter ending December 2024. The company faced a decline in profit after tax and net sales, yet it maintains strong management efficiency and healthy long-term growth, supported by significant institutional holdings.
Natco Pharma, a midcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation adjustment that reflects the current dynamics of its financial performance. The company reported flat financial results for the quarter ending December 2024, with a notable decline in profit after tax, which stood at Rs 133.00 crore, marking a significant drop compared to the previous four-quarter average. Additionally, net sales reached their lowest point at Rs 474.80 crore, while the profit before depreciation, interest, and taxes also recorded a low of Rs 38.80 crore.Despite these challenges, Natco Pharma maintains a strong management efficiency, evidenced by a high return on equity of 15.27% and a low debt-to-equity ratio. The company has demonstrated healthy long-term growth, with operating profit increasing at an annual rate of 30.72%. Furthermore, it boasts a favorable valuation with a price-to-book ratio of 2.4, trading at a discount relative to its peers.
The stock's technical indicators suggest a bearish trend, influenced by various factors. However, the presence of high institutional holdings at 23.51% indicates a level of confidence from investors with substantial analytical resources.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
